/Quest%20Diagnostics%2C%20Inc_%20inside%20office-by%20Kit%20Leong%20via%20Shutterstock.jpg)
With a market cap of about $15.7 billion, New Jersey-based Quest Diagnostics Incorporated (DGX) is a global leader in diagnostic testing and services. It develops and delivers a wide range of diagnostic information services, including routine, non-routine, and advanced clinical testing, as well as anatomic pathology and other specialized diagnostic services. The company is scheduled to disclose its fiscal Q2 earnings results on Tuesday, July 23.
Ahead of this event, analysts are expecting DGX to report a profit of $2.30 per share, remaining flat year over year. However, the company has an impressive track record of surpassing Wall Street's bottom-line estimates in each of the last four quarters. The company's adjusted EPS in the last reported quarter remained flat year over year at $2.04 but managed to outshine the consensus EPS estimate by nearly 9.7%.
